**Specifications table**Subject*Biology*Specific subject area*Genetics*Type of data*Table*How data were acquired*MALDI/TOF mass spectrometry using Sequenom MassARRAY 4.0 platform (Agena Bioscience™)*Data format*Raw and analyzed data*Parameters for data collection*About 5 ml of whole blood was collected from each study subject into a plastic vial (Vacutainer®) with 0.5M EDTA (рН=8.0). Genomic DNA was isolated using standard method of phenol-chloroform extraction and purification. DNA samples of good quality (concentration 10-15 ng/mL, purity А260/А280=1.7-2.0) were included for genotyping. About 5% of blind replicate samples were included for quality control of genotyping, and the repeatability test resulted in a 100% concordance rate.*Description of data collection*The quality of isolated DNA was assessed by Nanodrop-2000 spectrophotometer. DNA samples were genotyped using Sequenom MassARRAY® iPLEX platform using a method of MALDI-TOF (matrix-assisted laser desorption/ ionization time-of-flight) mass spectrometry. Assay Design Suite 1.0 was used to design a multiplex genotyping assay (http:// agenabio.com/assay-design-suite-10-software).*Data source location*Belgorod, Russia*Data accessibility*The data is available with this article*

Value of the data {#sec0001a}
=================

•The frequencies of alleles, genotypes and haplotypes for five SNPs such as rs1063192, rs7865618, rs2157719, rs944800 and rs4977756 of the *CDKN2B-AS1* gene are presented separately for entire sample, males and females with POAG from Russian population.•The data on the allele, genotype and haplotypes frequencies represent a resource for conducting meta-analyses of genetic studies on POAG.•Allele, genotype and haplotype frequencies of the *CDKN2B-AS1* gene polymorphisms and linkage disequilibrium values can be used as reference data for further population and genetic association studies of common diseases.

1. Data Description {#sec0001}
===================

The dataset represents the raw data (supplementary Table), frequencies of alleles, genotypes ([Table 1](#tbl0001){ref-type="table"}) and haplotypes ([Table 2](#tbl0002){ref-type="table"}) for five SNPs (rs1063192, rs7865618, rs2157719, rs944800 and rs4977756) of the *CDKN2B-AS* gene in Russian patients with POAG. These SNPs are found to be associated with the risk of POAG in previously published GWAS ([Table 3](#tbl0003){ref-type="table"}) [@bib0001], [@bib0002], [@bib0003], [@bib0004], [@bib0005], [@bib0006], [@bib0007], [@bib0008], [@bib0009], [@bib0010]. These SNPs possess the regulatory potential ([Table 4](#tbl0004){ref-type="table"}), as demonstrated by several eQTLs ([Table 5](#tbl0005){ref-type="table"}) and splicing QTLs ([Table 6](#tbl0006){ref-type="table"}). The frequencies of alleles, genotypes and haplotypes for the SNPs are provided separately for three groups: entire sample, females and males. No significant differences in the allele, genotype and haplotype frequencies were found between the males and females groups.Table 1The frequencies of alleles and genotypes for SNPs rs1063192, rs7865618, rs2157719, rs944800 and rs4977756 *CDKN2B-AS1* gene in Russian patients with POAG.Table 1SNP genotype or alleleAll (n=536)Female (n=290)Male (n=246)nfrequencynfrequencynfrequencyrs1063192GG1040.1940590.2034450.1829AG2560.47761340.46211220.4959AA1760.3284970.3345790.3212G4640.43282520.43452120.4309A6080.56723280.56552800.5691rs7865618GG940.1753520.1793420.1707AG2630.49071390.47931240.5041AA1790.3340990.3414800.3252G4510.42072430.41902080.4228A6210.57933370.58102840.5772rs2157719GG850.1585450.1552400.1626AG2490.46461350.46551140.4634AA2020.37691100.3793920.3740G4190.39092250.3879110.3943A6530.60913550.61212150.6057rs944800AA640.1194320.1103320.1301GA2410.44961300.44831110.4512GG2310.43101280.44141030.4187A3690.34421940.33451750.3557G7030.65583860.66553170.6443rs4977756GG1000.1866610.2104390.1585AG2860.53361540.53101320.5366AA1500.2798750.2586750.3049G4860.45342760.47592100.4268A5860.54663040.52412820.5732Table 2The frequencies of haplotypes for SNPs rs1063192, rs7865618, rs2157719, rs944800 and rs4977756 *CDKN2B-AS1* gene in Russian patients with POAG.Table 2Haplotype (rs1063192-rs7865618-rs2157719-rs944800-rs4977756)All (n=536), frequencyFemale (n=290), frequencyMale (n=246), frequencyGGGAG0.22210.21970.2304AGGAG0.01270.01250.0130GAGAG0.02200.01890.0272AAGAG0.01010.01370.0068GGAAG0.01200.01850.0054GGGGG0.05050.06280.0434GGAGG0.03730.03610.0397AAAGG0.07130.08590.0641GGGAA0.02620.02110.0359AAAAA0.02990.02650.0377AGGGA0.01330.01780.0096AAGGA0.01410.01550.0136GGAGA0.01540.01170.0208AGAGA0.01910.01890.0198GAAGA0.03180.04240.0217AAAGA0.38900.37790.4110Table 3The literature data about associations of the studied polymorphisms *CDKN2B-AS1* gene with POAG and optic disc characteristics (GWAS data).Table 3SNPPosition (hg38)PhenotypeAssociation (significance)(associated allele)Referencers106319222003368POAG\
Vertical cup-disc ratioOR= 0.79 (p=5 × 10^−11^) (T)\
β = -0.01 mm^2^ (p=4 × 10^−15^) (G)[@bib0001]\
[@bib0002]rs786561822031006POAG\
Vertical cup-disc ratio\
Optic cup areaOR= 1.78 (p=9 × 10^−11^) (A)\
β = -0.013 unit (p=5 × 10^−24^) (G)\
β = -0.023 unit (p=1 × 10^−21^) (G)[@bib0003]\
[@bib0004]\
[@bib0005]rs215771922033367POAG\
POAG\
Vertical cup-disc ratioOR= 1.45 (p=2 × 10^−18^)\
OR= 1.41 (p= 3 × 10^−33^)\
β = -0.013 unit (p=4 × 10^−35^)[@bib0006]\
[@bib0007]\
[@bib0008]rs94480022050899POAGOR= 1.33 (p=4 × 10^−14^) (G)[@bib0009]rs497775622068653POAGOR= 1.48 (p= 7 × 10^−30^) (A)[@bib0010]Table 4Regulatory effects of the 5 SNPs of the CDKN2B-AS1 gene (HaploReg, v4.1, update 05.11.2015) ([https://pubs.broadinstitute.org/mammals/haploreg/haploreg.ph](http://https://pubs.broadinstitute.org/mammals/haploreg/haploreg.ph){#interref0001}Table 4chrpos (hg38)variantRefAltAFRAMRASNEURSiPhyPromoterEnhancerDNAseProteinsMotifsNHGRI/EBIGRASP QTLSelected eQTLGENCODEdbSNPfreqfreqfreqfreqconshistone markshistone marksboundchangedGWAS hitshitshitsgenesfunc annot922003368rs1063192GA0.990.790.820.57SKINAIRE,GATA,Tgif12 hits3 hitsCDKN2B3′-UTR922031006rs7865618GA0.990.80.90.58BLD, SKIN3 hits4 hitsRP11-145E5.5intronic922033367rs2157719CT0.990.80.90.58BRST, SKIN6 tissuesPou2f2,Zfp1873 hits4 hitsCDKN2B-AS1intronic922050899rs944800AG0.990.860.90.6812 tissues4 tissuesGATACDKN2B-AS1intronic922068653rs4977756GA0.670.780.790.6BRN4 hits2 hitsCDKN2B-AS1intronicTable 5The cis-eQTL values of the 4 SNPs of the *CDKN2B-AS1* gene. (according to Genotype-Tissue Expression (GTEx) ([http://www.gtexportal.org/](http://http://www.gtexportal.org/){#interref0002})).Table 5SNPGene expressionReference alleleAlternative alleleEffect Size (β)P-ValueTissuers1063192*CDKN2A*GA0.330.000031Brain - Cortex*CDKN2B*GA-0.140.000051Muscle - Skeletalrs7865618*CDKN2A*GA0.330.000045Brain - Cortex*CDKN2B*GA-0.140.000085Muscle - Skeletalrs2157719*CDKN2A*CT0.330.000045Brain - Cortex*CDKN2B*CT-0.140.00009Muscle - Skeletalrs944800*CDKN2B-AS1*AG0.260.0000026Cells - Transformed fibroblastsTable 6The sQTL values of the 5 SNPs of the *CDKN2B-AS1* gene (according to Genotype-Tissue Expression (GTEx) ([http://www.gtexportal.org/](http://http://www.gtexportal.org/){#interref0003})).Table 6SNPGene SymbolReference alleleAlternative alleleIntron IdEffect Size (β)P-ValueTissuers1063192*CDKN2B-AS1*GA21995161:22046751:clu_552700.477.9e-9Pituitary*RP11-149I2.4*GA21995161:22046751:clu_552700.477.9e-9Pituitaryrs7865618*CDKN2B-AS1*GA21995161:22046751:clu_552700.471.2e-8Pituitary*RP11-149I2.4*GA21995161:22046751:clu_552700.471.2e-8Pituitaryrs2157719*CDKN2B-AS1*CT21995161:22046751:clu_552700.471.3e-8Pituitary*RP11-149I2.4*CT21995161:22046751:clu_552700.471.3e-8Pituitaryrs944800*CDKN2B-AS1*AG21995161:22046751:clu_552700.40.000004Pituitary*RP11-149I2.4*AG21995161:22046751:clu_552700.40.000004Pituitaryrs4977756*CDKN2B-AS1*GA21995161:22046751:clu_552700.439.3e-8Pituitary*RP11-149I2.4*GA21995161:22046751:clu_552700.439.3e-8Pituitary

2. Experimental Design, Materials, and Methods {#sec0002}
==============================================

2.1. Study subjects {#sec0003}
-------------------

A study sample was comprised of 536 patients with POAG, including 290 females and 246 males. The study participants were examined at the Division of Eye Microsurgery of Saint Joasaph\'s Belgorod Regional Clinical Hospital. The patients with POAG were unrelated Russians, residents of the Central Russia [@bib0011]. The subjects were enrolled for the study according to criteria described elsewhere [@bib0012]. All study participants signed a written informed consent in accordance with the principles of the Helsinki Declaration.

2.2. DNA analysis {#sec0004}
-----------------

Whole blood sample (5 ml) from each participant was drawn by a certified nurse into a plastic vial (Vacutainer®) with 0.5M EDTA (рН=8.0). Total DNA was isolated from buffy coat using standard phenol-chloroform extraction method [@bib0013]. DNA quality was assessed by Nanodrop-2000 spectrophotometer (Thermo Scientific, Inc.). DNA samples of good quality (concentration 10-15 ng/mL, purity А260/А280=1.7-2.0) were included for genotyping.

Five SNPs such as rs1063192, rs7865618, rs2157719, rs944800 and rs4977756 of the *CDKN2B-AS* gene were selected for the study according to the following criteria \[[@bib0014],[@bib0015]\]: 1) SNP showed an association with POAG by GWAS, 2) SNP possesses the regulatory potential, 3) SNP has eQTLs and/or sQTLs, 4) minor allele frequency, MAF \> 5%.

All selected SNPs were associated with POAG in previously published GWAS ([Table 3](#tbl0003){ref-type="table"}). These SNPs have the regulatory potential ([Table 4](#tbl0004){ref-type="table"}), eQTLs ([Table 5](#tbl0005){ref-type="table"}) and sQTLs ([Table 6](#tbl0006){ref-type="table"}), as assessed by the HaploReg v4.1 ([https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php](http://https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php){#interref0004}) and GTExportal recourses ([http://www.gtexportal.org](http://http://www.gtexportal.org){#interref0005}).

DNA samples were genotyped using the MALDI‐TOF mass spectrometry iPLEX platform (Agena Bioscience Inc, San Diego, CA). Concentration of DNA varied from 10 to 15 ng/mL. Assay Design Suite 1.0 (http:// agenabio.com/assay-design-suite-10-software) was used to design a multiplex genotyping assay. About 5% of blind replicate samples were included for quality control of genotyping, and the repeatability test resulted in a 100% concordance rate.

2.3. Statistical analysis {#sec0005}
-------------------------

Allele frequencies were estimated by the gene counting method, and the chi-square test was applied to identify significant departures from Hardy--Weinberg equilibrium (HWE). Differences in allele, genotype and haplotype frequencies between the study groups (females and males) were analyzed by the Kruskal-Wallis test. The haplotypes for the SNPs of the *CDKN2B-AS1* gene were constructed using an algorithm implemented in the PLINK software, v. 2.050 [@bib0016] ([http://zzz.bwh.harvard.edu/plink/](http://http://zzz.bwh.harvard.edu/plink/){#interref0006}).

Declaration of Competing Interest
=================================

The authors declare that they have no competing financial interests or personal relationships which have, or could be perceived to have, influenced the work reported in this article.

Appendix. Supplementary materials {#sec0007}
=================================

Image, application 1Image, application 2

The study was supported by grant of 10.13039/501100011051President of the Russian Federation (NS-2609.2020.7).

Supplementary material associated with this article can be found, in the online version, at doi:[10.1016/j.dib.2020.105722](https://doi.org/10.1016/j.dib.2020.105722){#interref0007}.
